
ICL Group (ICL): Potash Momentum vs. Leverage
ICL is benefiting from stronger potash, bromine, and specialty product momentum, but elevated leverage and weak historical earnings keep the stock in Hold territory.
Everything tagged "specialty chemicals" across the TickerSpark archives.

ICL is benefiting from stronger potash, bromine, and specialty product momentum, but elevated leverage and weak historical earnings keep the stock in Hold territory.

IFF is showing better operating momentum as Taste, Scent, and Health & Biosciences grow, but heavy debt and a still-premium valuation keep the stock at Hold.

DuPont posted 5.0% organic growth, 31% adjusted EPS growth, and stronger margins in Q3 2026, while raising full-year guidance. Valuation is reasonable on forward earnings, but execution and cyclical end-market risks remain.

Linde delivered another strong quarter with 9% sales growth, record adjusted EPS, and an $11.0 billion project backlog. The stock remains a Buy, but valuation is rich enough that upside depends on continued execution.

Ecolab posted 10% reported sales growth and 11% EPS growth in Q2 2026, with high-tech and life sciences driving the next leg of expansion. The stock is high quality, but valuation and leverage keep the rating at Hold.

H.B. Fuller is showing improving margins, solid cash generation, and a credible medical adhesives growth story. Leverage and acquisition integration risk keep the stock in Hold territory despite attractive valuation.

Solstice Advanced Materials posted 11% revenue growth in 2Q26 and raised full-year guidance, with refrigerants, electronic materials and nuclear services driving the story. Leverage, margin pressure and the Element Solutions deal keep the risk profile elevated.

Seven specialty chemicals stocks span fuel additives, life-science ingredients, activated carbon, petroleum additives, and electronics materials in a November 2026 countdown.

Westlake is a Hold as cost-cutting and a 2026 earnings rebound could help, but weak Q1 results and uneven earnings execution keep the setup cautious.

SOLS looks like a stock getting punished for deal shock more than for a broken core business. The acquisition risk is real, but the selloff has run ahead of a company that just posted 10% quarterly sales growth, reaffirmed guidance, and still carries constructive analyst support.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime